Clinical Trials · NCT03735537
Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- University of Edinburgh
- Enrollment
- 350
- Start date
- Nov 2016
- Locations
- 23 sites, Ireland, United Kingdom
- Primary endpoint
- Incident clinical fractures validated by x-ray or other imaging